Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Corp.

www.celgene.com

Latest From Celgene Corp.

Orphan AML Products Face CHMP Questioning

Companies developing new AML treatments are among those being called before the European Medicines Agency this week for questioning over marketing applications approaching the end of the review process. 

Europe Drug Review

Acceleron Ends ACE-083 FSHD Testing After Phase II Failure

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.

Neurology Clinical Trials

Biopharma Quarterly Dealmaking Statistics, Q2 2019

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

Market Intelligence Deals

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register